Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

671
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
671
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

316
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
316
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.3K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.3K
Male Sexual Response: Erection & Ejaculation01:17

Male Sexual Response: Erection & Ejaculation

24.1K
Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
24.1K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

58
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
58
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

556
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
556

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Percutaneous sacral neurostimulation of penile erection during radical prostatectomy: surgical technique.

Translational andrology and urology·2026
Same author

Periprocedural anti-thrombotic therapy and priapism recurrence after surgical shunting: a propensity-matched analysis.

The journal of sexual medicine·2026
Same author

Predicting major ischemic priapism: a novel dynamic nomogram based on recurrent ischemic priapism risk factors.

The journal of sexual medicine·2026
Same author

Changes in sexual quality of life in patients with stress urinary incontinence treated with an artificial urinary sphincter; analysis of the artificial urinary sphincter clinical outcomes trial (AUSCO).

The journal of sexual medicine·2026
Same author

Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial.

JAMA internal medicine·2026
Same author

Safety and tolerability of a novel implantable neurostimulator to improve erectile function: a pilot study in patients with spinal cord injury.

The journal of sexual medicine·2026

Related Experiment Video

Updated: Mar 1, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

1.1K

Research in pharmacotherapy for erectile dysfunction.

Ji-Kan Ryu1, Jun-Kyu Suh1, Arthur L Burnett2

  • 1National Research Center for Sexual Medicine and Department of Urology, Inha University School of Medicine, Incheon 400-711, Korea.

Translational Andrology and Urology
|May 26, 2017
PubMed
Summary

New erectile dysfunction (ED) treatments are being developed beyond oral phosphodiesterase-5 (PDE5) inhibitors. Promising preclinical research focuses on biotherapies like angiogenesis and neural regeneration for damaged erectile tissue.

Keywords:
Erectile dysfunction (ED)clinical trialpharmacotherapypreclinical studies

More Related Videos

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
08:03

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Published on: June 6, 2018

15.2K
Intracavernous Pressure Recording in a Cavernous Nerve Injury Rat Model
05:48

Intracavernous Pressure Recording in a Cavernous Nerve Injury Rat Model

Published on: September 20, 2021

2.0K

Related Experiment Videos

Last Updated: Mar 1, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

1.1K
Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
08:03

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Published on: June 6, 2018

15.2K
Intracavernous Pressure Recording in a Cavernous Nerve Injury Rat Model
05:48

Intracavernous Pressure Recording in a Cavernous Nerve Injury Rat Model

Published on: September 20, 2021

2.0K

Area of Science:

  • Urology
  • Pharmacology
  • Regenerative Medicine

Background:

  • Oral phosphodiesterase-5 (PDE5) inhibitors are standard for erectile dysfunction (ED), but efficacy is limited in patients with diabetes or post-prostatectomy.
  • Alternative therapeutic pathways are under investigation to address ED in non-responsive patient groups.

Purpose of the Study:

  • To review current and preclinical therapeutic targets for erectile dysfunction (ED).
  • To discuss pharmacotherapy and biotherapy approaches for ED treatment.

Main Methods:

  • Review of clinical and preclinical studies on novel ED therapeutic targets.
  • Categorization of agents into centrally acting (dopamine, melanocortin receptors) and peripherally acting (soluble guanylate cyclase, Rho-kinase, Maxi-K channel).
  • Exploration of biotherapies including therapeutic angiogenesis, neural regeneration, and anti-fibrosis strategies.

Main Results:

  • Several novel pharmacotherapies targeting alternative pathways are in clinical development but not yet marketed.
  • Preclinical studies show promising results for biotherapies aimed at regenerating erectile tissue.

Conclusions:

  • Current alternative pharmacotherapies for ED face market entry challenges.
  • Biotherapies hold significant promise for regenerating damaged erectile tissue and treating ED, particularly in difficult-to-treat populations.